REFERENCES
1. Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020. Neuro Oncol. 2023;25:iv1-iv99.
2. Torrisi F, D'Aprile S, Denaro S, et al. Epigenetics and metabolism reprogramming interplay into glioblastoma: novel insights on immunosuppressive mechanisms. Antioxidants. 2023;12:220.
3. Rezaee A, Tehrany PM, Tirabadi FJ, et al. Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: function of non-coding RNAs. Biomed Pharmacother. 2023;165:115187.
4. Ghannad-Zadeh K, Ivanova A, Wu M, et al. One-carbon-mediated purine synthesis underlies temozolomide resistance in glioblastoma. Cell Death Dis. 2024;15:774.
5. Pervjakova N, Kasela S, Morris AP, et al. Imprinted genes and imprinting control regions show predominant intermediate methylation in adult somatic tissues. Epigenomics. 2016;8:789-99.
6. van Eijk KR, de Jong S, Boks MP, et al. Genetic analysis of DNA methylation and gene expression levels in whole blood of healthy human subjects. BMC Genomics. 2012;13:636.
7. Maunakea AK, Nagarajan RP, Bilenky M, et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010;466:253-7.
8. Karpf AR, Matsui S. Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer Res. 2005;65:8635-9.
9. Guo JU, Su Y, Shin JH, et al. Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain. Nat Neurosci. 2014;17:215-22.
10. Schaffner SL, Wassouf Z, Hentrich T, Nuesch-Germano M, Kobor MS, Schulze-Hentrich JM. Distinct impacts of alpha-synuclein overexpression on the hippocampal epigenome of mice in standard and enriched environments. Neurobiol Dis. 2023;186:106274.
11. Perzel Mandell KA, Eagles NJ, Wilton R, et al. Genome-wide sequencing-based identification of methylation quantitative trait loci and their role in schizophrenia risk. Nat Commun. 2021;12:5251.
12. Lorente A, Mueller W, Urdangarín E, et al. RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol. 2009;19:279-92.
13. Shukla S, Pia Patric IR, Thinagararjan S, et al. A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-κB nexus. Cancer Res. 2013;73:6563-73.
14. Liang WW, Lu RJ, Jayasinghe RG, et al. Clinical Proteomic Tumor Analysis Consortium. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin. Cancer Cell. 2023;41:1567-1585.e7.
15. Carlos-Escalante JA, Mejía-Pérez SI, Soto-Reyes E, et al. Deep DNA sequencing of MGMT, TP53 and AGT in mexican astrocytoma patients identifies an excess of genetic variants in women and a predictive biomarker. J Neurooncol. 2023;161:165-74.
16. Zhou J, Tong F, Zhao J, et al. Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance. Cancer Biol Med. 2023;20:385-400.
17. Barciszewska AM, Gurda D, Głodowicz P, Nowak S, Naskręt-Barciszewska MZ. A new epigenetic mechanism of temozolomide action in glioma cells. PLoS One. 2015;10:e0136669.
18. Sareen H, Ma Y, Becker TM, Roberts TL, de Souza P, Powter B. Molecular biomarkers in glioblastoma: a systematic review and meta-analysis. Int J Mol Sci. 2022;23:8835.
19. Chen X, Zhang M, Gan H, et al. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun. 2018;9:2949.
20. Shin YJ, Sa JK, Lee Y, et al. PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma. J Exp Med. 2019;216:1120-34.
21. Singh SK, Wang Y, Habib A, et al. TP53-PTEN-NF1 depletion in human brain organoids produces a glioma phenotype in vitro. Front Oncol. 2023;13:1279806.
22. Wiencke JK, Zheng S, Jelluma N, et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol. 2007;9:271-9.
23. Brun M, Jain S, Monckton EA, Godbout R. Nuclear factor I represses the notch effector HEY1 in glioblastoma. Neoplasia. 2018;20:1023-37.
24. Li Q, Wang J, Ma X, Wang M, Zhou L. POFUT1 acts as a tumor promoter in glioblastoma by enhancing the activation of notch signaling. J Bioenerg Biomembr. 2021;53:621-32.
25. Kopan R, Ilagan MX. The canonical notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137:216-33.
26. Bazzoni R, Bentivegna A. Role of notch signaling pathway in glioblastoma pathogenesis. Cancers. 2019;11:292.
27. Saito N, Aoki K, Hirai N, et al. Effect of notch expression in glioma stem cells on therapeutic response to chemo-radiotherapy in recurrent glioblastoma. Brain Tumor Pathol. 2015;32:176-83.
28. Yu JB, Jiang H, Zhan RY. Aberrant notch signaling in glioblastoma stem cells contributes to tumor recurrence and invasion. Mol Med Rep. 2016;14:1263-8.
29. Wang Y, Sun Q, Geng R, et al. Notch intracellular domain regulates glioblastoma proliferation through the notch1 signaling pathway. Oncol Lett. 2021;21:303.
30. Tsung AJ, Guda MR, Asuthkar S, et al. Methylation regulates HEY1 expression in glioblastoma. Oncotarget. 2017;8:44398-409.
31. Götze S, Wolter M, Reifenberger G, Müller O, Sievers S. Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int J Cancer. 2010;126:2584-93.
32. Lambiv WL, Vassallo I, Delorenzi M, et al. The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol. 2011;13:736-47.
33. Horiguchi K, Tomizawa Y, Tosaka M, et al. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Oncogene. 2003;22:7862-5.
34. Jayaram H, Hoelper D, Jain SU, et al. S-adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3. Proc Natl Acad Sci U S A. 2016;113:6182-7.
35. Wilson JR. Determination of histone methyltransferase structure by crystallography. In: margueron R, Holoch D, editors. Histone methyltransferases. New York: Springer US; 2022. pp. 137-47.
36. Chinot OL, Barrié M, Fuentes S, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol. 2007;25:1470-5.
37. Zhang J, Chen L, Han L, et al. EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma. Cancer Lett. 2015;356:929-36.
38. Vinchure OS, Sharma V, Tabasum S, et al. Polycomb complex mediated epigenetic reprogramming alters TGF-β signaling via a novel EZH2/miR-490/TGIF2 axis thereby inducing migration and EMT potential in glioblastomas. Int J Cancer. 2019;145:1254-69.
39. Yin Y, Qiu S, Li X, Huang B, Xu Y, Peng Y. EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment. J Neuroinflammation. 2017;14:220.
40. McCornack C, Woodiwiss T, Hardi A, Yano H, Kim AH. The function of histone methylation and acetylation regulators in GBM pathophysiology. Front Oncol. 2023;13:1144184.
41. Weiss VH, McBride AE, Soriano MA, Filman DJ, Silver PA, Hogle JM. The structure and oligomerization of the yeast arginine methyltransferase, Hmt1. Nat Struct Biol. 2000;7:1165-71.
42. Fischle W, Wang Y, Jacobs SA, Kim Y, Allis CD, Khorasanizadeh S. Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by polycomb and HP1 chromodomains. Genes Dev. 2003;17:1870-81.
44. Walport LJ, Hopkinson RJ, Chowdhury R, et al. Arginine demethylation is catalysed by a subset of JmjC histone lysine demethylases. Nat Commun. 2016;7:11974.
45. Farrelly LA, Thompson RE, Zhao S, et al. Histone serotonylation is a permissive modification that enhances TFIID binding to H3K4me3. Nature. 2019;567:535-9.
46. Young D, Guha C, Sidoli S. The role of histone H3 lysine demethylases in glioblastoma. Cancer Metastasis Rev. 2023;42:445-54.
47. Ye L, Gu L, Wang Y, et al. Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data. CNS Neurosci Ther. 2024;30:e14649.
48. Schneider J, Bajwa P, Johnson FC, Bhaumik SR, Shilatifard A. Rtt109 is required for proper H3K56 acetylation: a chromatin mark associated with the elongating RNA polymerase II. J Biol Chem. 2006;281:37270-4.
49. Schuettengruber B, Martinez AM, Iovino N, Cavalli G. Trithorax group proteins: switching genes on and keeping them active. Nat Rev Mol Cell Biol. 2011;12:799-814.
50. Gallo M, Ho J, Coutinho FJ, et al. A tumorigenic MLL-homeobox network in human glioblastoma stem cells. Cancer Res. 2013;73:417-27.
51. Kim E, Kim M, Woo DH, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013;23:839-52.
52. Chen YN, Hou SQ, Jiang R, Sun JL, Cheng CD, Qian ZR. EZH2 is a potential prognostic predictor of glioma. J Cell Mol Med. 2021;25:925-36.
53. Zhang Y, Yu X, Chen L, Zhang Z, Feng S. EZH2 overexpression is associated with poor prognosis in patients with glioma. Oncotarget. 2017;8:565-73.
54. Suvà ML, Riggi N, Janiszewska M, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 2009;69:9211-8.
56. Yue Q, Wang Z, Shen Y, et al. Histone H3K9 lactylation confers temozolomide resistance in glioblastoma via LUC7L2-mediated MLH1 intron retention. Adv Sci. 2024;11:e2309290.
57. Kaur E, Nair J, Ghorai A, et al. Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevents glioblastoma recurrence. Neuro Oncol. 2020;22:1785-96.
58. Venneti S, Thompson CB. Metabolic modulation of epigenetics in gliomas. Brain Pathol. 2013;23:217-21.
59. Shankar SR, Bahirvani AG, Rao VK, Bharathy N, Ow JR, Taneja R. G9a, a multipotent regulator of gene expression. Epigenetics. 2013;8:16-22.
60. Tao H, Li H, Su Y, et al. Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells. Mol Cell Biochem. 2014;394:23-30.
61. Bao L, Chen Y, Lai HT, et al. Methylation of hypoxia-inducible factor (HIF)-1α by G9a/GLP inhibits HIF-1 transcriptional activity and cell migration. Nucleic Acids Res. 2018;46:6576-91.
62. Melcher M, Schmid M, Aagaard L, Selenko P, Laible G, Jenuwein T. Structure-function analysis of SUV39H1 reveals a dominant role in heterochromatin organization, chromosome segregation, and mitotic progression. Mol Cell Biol. 2000;20:3728-41.
63. Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ 3rd. SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev. 2002;16:919-32.
64. Spyropoulou A, Gargalionis A, Dalagiorgou G, et al. Role of histone lysine methyltransferases SUV39H1 and SETDB1 in gliomagenesis: modulation of cell proliferation, migration, and colony formation. Neuromolecular Med. 2014;16:70-82.
65. Sepsa A, Levidou G, Gargalionis A, et al. Emerging role of linker histone variant H1x as a biomarker with prognostic value in astrocytic gliomas. A multivariate analysis including trimethylation of H3K9 and H4K20. PLoS One. 2015;10:e0115101.
66. Feoli A, Iannelli G, Cipriano A, et al. Identification of a protein arginine methyltransferase 7 (PRMT7)/protein arginine methyltransferase 9 (PRMT9) inhibitor. J Med Chem. 2023;66:13665-83.
67. Husmann D, Gozani O. Histone lysine methyltransferases in biology and disease. Nat Struct Mol Biol. 2019;26:880-9.
68. Li XX, Xu JK, Su WJ, et al. The role of KDM4A-mediated histone methylation on temozolomide resistance in glioma cells through the HUWE1/ROCK2 axis. Kaohsiung J Med Sci. 2024;40:161-74.
69. Zhong C, Tao B, Li X, et al. HOXA-AS2 contributes to regulatory T cell proliferation and immune tolerance in glioma through the miR-302a/KDM2A/JAG1 axis. Cell Death Dis. 2022;13:160.
70. Wang L, Lang B, Zhou Y, Ma J, Hu K. Up-regulation of miR-663a inhibits the cancer stem cell-like properties of glioma via repressing the KDM2A-mediated TGF-β/SMAD signaling pathway. Cell Cycle. 2021;20:1935-52.
71. Liau BB, Sievers C, Donohue LK, et al. Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell Stem Cell. 2017;20:233-246.e7.
72. Banasavadi-Siddegowda YK, Welker AM, An M, et al. PRMT5 as a druggable target for glioblastoma therapy. Neuro Oncol. 2018;20:753-63.
73. Han X, Li R, Zhang W, et al. Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. J Neurooncol. 2014;118:61-72.
74. Holmes B, Benavides-Serrato A, Saunders JT, et al. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma. J Neurooncol. 2019;145:11-22.
75. Wang S, Tan X, Yang B, et al. The role of protein arginine-methyltransferase 1 in gliomagenesis. BMB Rep. 2012;45:470-5.
76. Banasavadi-Siddegowda YK, Russell L, Frair E, et al. PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells. Oncogene. 2017;36:263-74.
77. Sachamitr P, Ho JC, Ciamponi FE, et al. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nat Commun. 2021;12:979.
78. Liao Y, Luo Z, Lin Y, et al. PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism. Cell Death Dis. 2022;13:943.
81. Shabane PS, Onufriev AV. Significant compaction of H4 histone tail upon charge neutralization by acetylation and its mimics, possible effects on chromatin structure. J Mol Biol. 2021;433:166683.
82. Lv D, Jia F, Hou Y, et al. Histone acetyltransferase KAT6A upregulates PI3K/AKT signaling through TRIM24 binding. Cancer Res. 2017;77:6190-201.
83. Vakoc CR, Sachdeva MM, Wang H, Blobel GA. Profile of histone lysine methylation across transcribed mammalian chromatin. Mol Cell Biol. 2006;26:9185-95.
84. Dali-Youcef N, Froelich S, Moussallieh FM, et al. Gene expression mapping of histone deacetylases and co-factors, and correlation with survival time and 1H-HRMAS metabolomic profile in human gliomas. Sci Rep. 2015;5:9087.
85. Li S, Chen X, Mao L, et al. Histone deacetylase 1 promotes glioblastoma cell proliferation and invasion via activation of PI3K/AKT and MEK/ERK signaling pathways. Brain Res. 2018;1692:154-62.
86. Diss E, Nalabothula N, Nguyen D, Chang E, Kwok Y, Carrier F. Vorinostat(SAHA) promotes hyper-radiosensitivity in wild type p53 human glioblastoma cells. J Clin Oncol Res. 2014:2.
87. Kim JH, Shin JH, Kim IH. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys. 2004;59:1174-80.
88. Li ZY, Li QZ, Chen L, et al. Histone deacetylase inhibitor RGFP109 overcomes temozolomide resistance by blocking NF-κB-dependent transcription in glioblastoma cell lines. Neurochem Res. 2016;41:3192-205.
89. Das ND, Chang JC, Hon CC, et al. Defining super-enhancers by highly ranked histone H4 multi-acetylation levels identifies transcription factors associated with glioblastoma stem-like properties. BMC Genomics. 2023;24:574.
90. Tao Z, Li X, Wang H, et al. BRD4 regulates self-renewal ability and tumorigenicity of glioma-initiating cells by enrichment in the notch1 promoter region. Clin Transl Med. 2020;10:e181.
91. Flaus A, Martin DM, Barton GJ, Owen-Hughes T. Identification of multiple distinct Snf2 subfamilies with conserved structural motifs. Nucleic Acids Res. 2006;34:2887-905.
92. Grüne T, Brzeski J, Eberharter A, et al. Crystal structure and functional analysis of a nucleosome recognition module of the remodeling factor ISWI. Mol Cell. 2003;12:449-60.
93. Tran HG, Steger DJ, Iyer VR, Johnson AD. The chromo domain protein chd1p from budding yeast is an ATP-dependent chromatin-modifying factor. EMBO J. 2000;19:2323-31.
94. Schubert HL, Wittmeyer J, Kasten MM, et al. Structure of an actin-related subcomplex of the SWI/SNF chromatin remodeler. Proc Natl Acad Sci U S A. 2013;110:3345-50.
95. Chen K, Yuan J, Sia Y, Chen Z. Mechanism of action of the SWI/SNF family complexes. Nucleus. 2023;14:2165604.
96. Di Giuseppe F, Ricci-Vitiani L, Pallini R, et al. Changes induced by P2X7 receptor stimulation of human glioblastoma stem cells in the proteome of extracellular vesicles isolated from their secretome. Cells. 2024;13:571.
97. Hodges C, Kirkland JG, Crabtree GR. The many roles of BAF (mSWI/SNF) and PBAF complexes in cancer. Cold Spring Harb Perspect Med. 2016;6:a026930.
98. Ganguly D, Sims M, Cai C, Fan M, Pfeffer LM. Chromatin remodeling factor BRG1 regulates stemness and chemosensitivity of glioma initiating cells. Stem Cells. 2018;36:1804-15.
99. Ji J, Xu R, Zhang X, et al. Actin like-6A promotes glioma progression through stabilization of transcriptional regulators YAP/TAZ. Cell Death Dis. 2018;9:517.
100. Yang C, He Y, Wang Y, et al. Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastoma. J Cell Mol Med. 2023;27:2770-81.
101. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302:1-12.
102. ParvizHamidi M, Haddad G, Ostadrahimi S, et al. Circulating miR-26a and miR-21 as biomarkers for glioblastoma multiform. Biotechnol Appl Biochem. 2019;66:261-5.
103. Wang Q, Li P, Li A, et al. Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res. 2012;31:97.
104. Mekala JR, Adusumilli K, Chamarthy S, Angirekula HSR. Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme. Metab Brain Dis. 2023;38:1801-29.
105. Hombach S, Kretz M. Non-coding RNAs: Classification, biology and functioning. In: Slaby O, Calin GA, editors. Non-coding RNAs in colorectal cancer. Cham: Springer International Publishing; 2016. pp. 3-17.
106. Sato K, Osaka E, Fujiwara K, et al. miRNA218 targets multiple oncogenes and is a therapeutic target for osteosarcoma. Oncol Rep. 2022;47:92.
107. Castro-Muñoz LJ, Ulloa EV, Sahlgren C, Lizano M, De La Cruz-Hernández E, Contreras-Paredes A. Modulating epigenetic modifications for cancer therapy (review). Oncol Rep. 2023;49:59.
108. Wang Z, Han Y, Li Q, Wang B, Ma J. LncRNA DLGAP1-AS1 accelerates glioblastoma cell proliferation through targeting miR-515-5p/ROCK1/NFE2L1 axis and activating Wnt signaling pathway. Brain Behav. 2021;11:e2321.
109. Zheng Q, Bao C, Guo W, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun. 2016;7:11215.
110. Sun J, Tian X, Zhang J, et al. Regulation of human glioma cell apoptosis and invasion by miR-152-3p through targeting DNMT1 and regulating NF2 : MiR-152-3p regulate glioma cell apoptosis and invasion. J Exp Clin Cancer Res. 2017;36:100.
111. Xiao S, Yang Z, Qiu X, et al. miR-29c contribute to glioma cells temozolomide sensitivity by targeting O6-methylguanine-DNA methyltransferases indirectely. Oncotarget. 2016;7:50229-38.
112. Gu X, Gong H, Shen L, Gu Q. MicroRNA-129-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting DNMT3A. Am J Transl Res. 2018;10:2834-47.
113. Du W, Chen D, Wei K, et al. MiR-10b-5p impairs TET2-mediated inhibition of PD-L1 transcription thus promoting immune evasion and tumor progression in glioblastoma. Tohoku J Exp Med. 2023;260:205-14.
114. Han L, Li Z, Jiang Y, Jiang Z, Tang L. SNHG29 regulates miR-223-3p/CTNND1 axis to promote glioblastoma progression via Wnt/β-catenin signaling pathway. Cancer Cell Int. 2019;19:345.
115. Li L, Shao MY, Zou SC, Xiao ZF, Chen ZC. MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44. J Neurooncol. 2019;141:19-30.
116. Subaiea GM, Syed RU, Afsar S, et al. Non-coding RNAs (ncRNAs) and multidrug resistance in glioblastoma: therapeutic challenges and opportunities. Pathol Res Pract. 2024;253:155022.
117. Chen H, Lu Q, Fei X, Shen L, Jiang D, Dai D. miR-22 inhibits the proliferation, motility, and invasion of human glioblastoma cells by directly targeting SIRT1. Tumour Biol. 2016;37:6761-8.
118. Munoz JL, Rodriguez-Cruz V, Rameshwar P. High expression of miR-9 in CD133+ glioblastoma cells in chemoresistance to temozolomide. J Cancer Stem Cell Res. 2015;3:e1003.
119. Chen G, Chen Z, Zhao H. MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1. J Cell Mol Med. 2020;24:5363-74.
120. Munoz JL, Walker ND, Mareedu S, et al. Cycling quiescence in temozolomide resistant glioblastoma cells is partly explained by microRNA-93 and -193-mediated decrease of cyclin D. Front Pharmacol. 2019;10:134.
121. Ren S, Xu Y. AC016405.3, a novel long noncoding RNA, acts as a tumor suppressor through modulation of TET2 by microRNA-19a-5p sponging in glioblastoma. Cancer Sci. 2019;110:1621-32.
122. Ahmadov U, Picard D, Bartl J, et al. The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma. Cell Death Dis. 2021;12:885.
123. Wu AC, Yang WB, Chang KY, et al. HDAC6 involves in regulating the lncRNA-microRNA-mRNA network to promote the proliferation of glioblastoma cells. J Exp Clin Cancer Res. 2022;41:47.
124. Wu P, Cai J, Chen Q, et al. Lnc-TALC promotes O6-methylguanine-DNA methyltransferase expression via regulating the c-Met pathway by competitively binding with miR-20b-3p. Nat Commun. 2019;10:2045.
125. Lu C, Wei Y, Wang X, et al. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Mol Cancer. 2020;19:28.
126. Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344:1396-401.
127. Yabo YA, Niclou SP, Golebiewska A. Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma. Neuro Oncol. 2022;24:669-82.
128. Roy-Camille R, Huten D, Gagna G, Laredo JD. Malignant bone tumors and giant cell tumors of the sacrum in adults. Rev Chir Orthop Reparatrice Appar Mot. 1987;73:82-91.
129. Safa AR, Saadatzadeh MR, Cohen-Gadol AA, Pollok KE, Bijangi-Vishehsaraei K. Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs. Genes Dis. 2015;2:152-63.
130. Lauko A, Lo A, Ahluwalia MS, Lathia JD. Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors. Semin Cancer Biol. 2022;82:162-75.
131. Gill BJ, Pisapia DJ, Malone HR, et al. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc Natl Acad Sci U S A. 2014;111:12550-5.
132. Bhat KPL, Balasubramaniyan V, Vaillant B, et al. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell. 2013;24:331-46.
133. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009;8:3274-84.
134. McCoy MG, Nyanyo D, Hung CK, et al. Endothelial cells promote 3D invasion of GBM by IL-8-dependent induction of cancer stem cell properties. Sci Rep. 2019;9:9069.
135. Bhutta BS, Alghoula F, Berim I. Hypoxia. In: StatPearls. Treasure Island (FL): 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482316/. [Last accessed on 21 Dec 2024].
136. Chinnaiyan P, Chowdhary S, Potthast L, et al. Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neuro Oncol. 2012;14:93-100.
137. Krauze AV, Myrehaug SD, Chang MG, et al. A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2015;92:986-92.
138. Turcan S, Fabius AW, Borodovsky A, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor decitabine. Oncotarget. 2013;4:1729-36.
139. Kratzsch T, Kuhn SA, Joedicke A, et al. Treatment with 5-azacitidine delay growth of glioblastoma xenografts: a potential new treatment approach for glioblastomas. J Cancer Res Clin Oncol. 2018;144:809-19.
140. Wu Q, Berglund AE, Macaulay RJ, Etame AB. Epigenetic activation of TUSC3 sensitizes glioblastoma to temozolomide independent of MGMT promoter methylation status. Int J Mol Sci. 2023;24:15179.
141. Romani M, Pistillo MP, Banelli B. Epigenetic targeting of glioblastoma. Front Oncol. 2018;8:448.
142. Wang J, Yang J, Li D, Li J. Technologies for targeting DNA methylation modifications: basic mechanism and potential application in cancer. Biochim Biophys Acta Rev Cancer. 2021;1875:188454.
143. Han X, Abdallah MOE, Breuer P, et al. Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma. Neoplasia. 2023;44:100929.
144. Tong F, Zhao JX, Fang ZY, et al. MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII. Pharmacol Res. 2023;187:106606.
145. Yao X, Hu JF, Daniels M, et al. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest. 2003;111:265-73.
146. Sharma RK, Calderon C, Vivas-Mejia PE. Targeting non-coding RNA for glioblastoma therapy: the challenge of overcomes the blood-brain barrier. Front Med Technol. 2021;3:678593.
147. Zhao J, Chen AX, Gartrell RD, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019;25:462-9.
148. Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010;119:487-94.
149. Lynes JP, Nwankwo AK, Sur HP, et al. Biomarkers for immunotherapy for treatment of glioblastoma. J Immunother Cancer. 2020;8:e000348.
150. Tancredi A, Gusyatiner O, Bady P, et al. BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression. Cell Death Dis. 2022;13:1037.
151. Singh MM, Johnson B, Venkatarayan A, et al. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma. Neuro Oncol. 2015;17:1463-73.
152. Sareddy GR, Viswanadhapalli S, Surapaneni P, Suzuki T, Brenner A, Vadlamudi RK. Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway. Oncogene. 2017;36:2423-34.
153. Alejo S, Palacios BE, Venkata PP, et al. Lysine-specific histone demethylase 1A (KDM1A/LSD1) inhibition attenuates DNA double-strand break repair and augments the efficacy of temozolomide in glioblastoma. Neuro Oncol. 2023;25:1249-61.
154. Fang Y, Liao G, Yu B. LSD1/KDM1A inhibitors in clinical trials: advances and prospects. J Hematol Oncol. 2019;12:129.
155. Voon HPJ, Udugama M, Lin W, et al. Inhibition of a K9/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma. Nat Commun. 2018;9:3142.
156. Lee DH, Kim GW, Yoo J, et al. Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc. Cell Death Dis. 2021;12:89.
157. Banelli B, Daga A, Forlani A, et al. Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells. Oncotarget. 2017;8:34896-910.
158. Romani M, Daga A, Forlani A, Pistillo MP, Banelli B. Targeting of histone demethylases KDM5A and KDM6B inhibits the proliferation of temozolomide-resistant glioblastoma cells. Cancers. 2019;11:878.
159. Chen R, Zhang M, Zhou Y, et al. The application of histone deacetylases inhibitors in glioblastoma. J Exp Clin Cancer Res. 2020;39:138.
160. Ellis HP, Greenslade M, Powell B, Spiteri I, Sottoriva A, Kurian KM. Current challenges in glioblastoma: intratumour heterogeneity, residual disease, and models to predict disease recurrence. Front Oncol. 2015;5:251.
161. Kusaczuk M, Krętowski R, Bartoszewicz M, Cechowska-Pasko M. Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line. Tumour Biol. 2016;37:931-42.
162. Sawa H, Murakami H, Ohshima Y, et al. Histone deacetylase inhibitors such as sodium butyrate and trichostatin a inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells. Brain Tumor Pathol. 2002;19:77-81.
163. Funck-Brentano E, Vizlin-Hodzic D, Nilsson JA, Nilsson LM. BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma. Epigenetics. 2021;16:54-63.
164. Chiao MT, Cheng WY, Yang YC, Shen CC, Ko JL. Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells. Autophagy. 2013;9:1509-26.
165. Alvarez AA, Field M, Bushnev S, Longo MS, Sugaya K. The effects of histone deacetylase inhibitors on glioblastoma-derived stem cells. J Mol Neurosci. 2015;55:7-20.
166. Urdiciain A, Erausquin E, Meléndez B, Rey JA, Idoate MA, Castresana JS. Tubastatin A, an inhibitor of HDAC6, enhances temozolomideinduced apoptosis and reverses the malignant phenotype of glioblastoma cells. Int J Oncol. 2019;54:1797-808.
167. Sun X, Klingbeil O, Lu B, et al. BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network. Nature. 2023;613:195-202.
168. Schreiber V, Amé JC, Dollé P, et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem. 2002;277:23028-36.
169. Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18:610-21.
170. Woodhouse BC, Dianova II, Parsons JL, Dianov GL. Poly(ADP-ribose) polymerase-1 modulates DNA repair capacity and prevents formation of DNA double strand breaks. DNA Repair. 2008;7:932-40.
171. Sim HW, Galanis E, Khasraw M. PARP inhibitors in glioma: a review of therapeutic opportunities. Cancers. 2022;14:1003.
172. Smith AJB, Apple A, Hugo A, Haggerty A, Ko EM. Prior authorization for FDA-approved PARP inhibitors in ovarian cancer. Gynecol Oncol Rep. 2024;52:101335.
173. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091-102.
174. Robson ME, Im SA, Senkus E, et al. OlympiAD extended follow-up for overall survival and safety: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer. 2023;184:39-47.
175. Messner S, Altmeyer M, Zhao H, et al. PARP1 ADP-ribosylates lysine residues of the core histone tails. Nucleic Acids Res. 2010;38:6350-62.
176. Hanna C, Kurian KM, Williams K, et al. Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. Neuro Oncol. 2020;22:1840-50.
177. McDonald MF, Hossain A, Momin EN, et al. Tumor-specific polycistronic miRNA delivered by engineered exosomes for the treatment of glioblastoma. Neuro Oncol. 2024;26:236-50.
178. Elshaer SS, Abulsoud AI, Fathi D, et al. miRNAs role in glioblastoma pathogenesis and targeted therapy: signaling pathways interplay. Pathol Res Pract. 2023;246:154511.
179. Mirzaei S, Mahabady MK, Zabolian A, et al. Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: current status with an emphasis on delivery systems. Life Sci. 2021;275:119368.
180. Bassot A, Dragic H, Haddad SA, et al. Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma. Cell Death Dis. 2023;14:630.
